Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 185

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)

Paschka, Peter, Du, Juan, Schlenk, Richard F., Gaidzik, Verena I., Bullinger, Lars, Corbacioglu, Andrea, Späth, Daniela, Kayser, Sabine, Schlegelberger, Brigitte, Krauter, Jürgen, Ganser, Arnold, Köhne, Claus-Henning, Held, Gerhard, von Lilienfeld-Toal, Marie, Kirchen, Heinz, Rummel, Mathias, Götze, Katharina, Horst, Heinz-August, Ringhoffer, Mark, Lübbert, Michael, Wattad, Mohammed, Salih, Helmut R., Kündgen, Andrea, Döhner, Hartmut, Döhner, Konstanze·2013·Blood

Abstract

In this study, we evaluated the impact of secondary genetic lesions in acute myeloid leukemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11. We studied 176 patients, all enrolled on prospective treatment trials, for secondary chromosomal aberrations and mutations in N-/KRAS, KIT, FLT3, and JAK2 (V617F) genes. Most frequent chromosomal aberrations were trisomy 22 (18%) and trisomy 8 (16%). Overall, 84% of patients harbored at least 1 gene mutation, with RAS being affected in 53% (45% NRAS; 13% KRAS) of the cases, followed by KIT (37%) and FLT3 (17%; FLT3-TKD [14%], FLT3-ITD [5%]). None of the secondary genetic lesions influenced achievement of complete remission. In multivariable analyses, KIT mutation (hazard ratio [HR] = 1.67; P = .04], log10(WBC) (HR = 1.33; P = .02), and trisomy 22 (HR = 0.54; P = .08) were relevant factors for relapse-free survival; for overall survival, FLT3 mutation (HR = 2.56; P = .006), trisomy 22 (HR = 0.45; P = .07), trisomy 8 (HR = 2.26; P = .02), age (difference of 10 years, HR = 1.46; P = .01), and therapy-related AML (HR = 2.13; P = .14) revealed as prognostic factors. The adverse effects of KIT and FLT3 mutations were mainly attributed to exon 8 and tyrosine kinase domain mutations, respectively. Our large study emphasizes the impact of both secondary chromosomal aberrations as well as gene mutations for outcome in AML with inv(16)/t (16;16).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2012-05-431486

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 185

Metadata

Authors
Paschka, P., Du, J., Schlenk, R. F., Gaidzik, V. I., Bullinger, L., Corbacioglu, A., Späth, D., Kayser, S., Schlegelberger, B., Krauter, J., Ganser, A., Köhne, C.-H., Held, G., von Lilienfeld-Toal, M., Kirchen, H., Rummel, M., Götze, K., Horst, H.-A., Ringhoffer, M., Lübbert, M., Wattad, M., Salih, H. R., Kündgen, A., Döhner, H., & Döhner, K.
Venue
Blood
Published
2013-01-03
Volume
121
Issue
1
Pages
170-177
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2001656423
Cited by
185
References
3
FWCI
7.30
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). https://app.cochat.ai/papers/10.1182/blood-2012-05-431486
The paper
Paschka, P., Du, J., Schlenk, R. F., Gaidzik, V. I., Bullinger, L., Corbacioglu, A., Späth, D., Kayser, S., Schlegelberger, B., Krauter, J., Ganser, A., Köhne, C.-H., Held, G., von Lilienfeld-Toal, M., Kirchen, H., Rummel, M., Götze, K., Horst, H.-A., Ringhoffer, M., . . . Döhner, K. (2013). Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). Blood. https://doi.org/10.1182/blood-2012-05-431486

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.